Literature DB >> 8788915

Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats.

R E See1, A M Lynch, M Aravagiri, C B Nemeroff, M J Owens.   

Abstract

Chronic neuroleptic administration has previously been shown to alter in vivo measures of dopaminergic function and lead to regionally selective increases in neurotensin levels. In the current study, female rats were administered chronic haloperidol for 6 months via subcutaneous silastic implants. After 24 weeks of administration, microdialysis probes were inserted into the lateral caudate putamen and the medial prefrontal cortex. Basal samples were collected prior to infusion of a high K+ concentration (100 mM KCl). Extracellular concentrations of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindoleacetic acid were assessed using HPLC. Chronic haloperidol-treated rats showed increased basal dopamine metabolite levels in the caudate putamen and an altered response to the effects of high K+ on 3,4-dihydroxyphenylacetic acid; no significant differences were seen with other analytes in the caudate putamen. Although basal concentrations were not different between groups in the prefrontal cortex, haloperidol-treated rats showed a significant attenuation of response to the effects of high K+ infusion on dopamine metabolite concentrations. Radioimmunoassay measurement of tissue neurotensin content showed highly significant elevations of neurotensin concentrations in the caudate putamen and nucleus accumbens, but not in other brain regions analyzed. These results suggest a confluence of altered dopamine and neurotensin function in the caudate putamen which may be related to motor side effects of haloperidol, whereas changes in prefrontal dopamine function are not associated with altered neurotensin levels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8788915     DOI: 10.1016/0006-8993(95)01114-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence.

Authors:  Mahendra Bishnoi; Kanwaljit Chopra; Lu Rongzhu; Shrinivas K Kulkarni
Journal:  Neurotox Res       Date:  2010-11-13       Impact factor: 3.911

2.  Ovariectomy results in lower plasma haloperidol levels in rats following chronic administration.

Authors:  J W Grimm; M Aravagiri; R E See
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

Review 3.  Neurotensin in reward processes.

Authors:  María Luisa Torruella-Suárez; Zoe A McElligott
Journal:  Neuropharmacology       Date:  2020-02-11       Impact factor: 5.250

4.  Development of cocaine sensitization before pregnancy affects subsequent maternal retrieval of pups and prefrontal cortical activity during nursing.

Authors:  M Febo; C F Ferris
Journal:  Neuroscience       Date:  2007-07-25       Impact factor: 3.590

Review 5.  Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders.

Authors:  Mona M Boules; Paul Fredrickson; Amber M Muehlmann; Elliott Richelson
Journal:  Behav Sci (Basel)       Date:  2014-06-13

Review 6.  Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.

Authors:  Willem Johan van den Brink; Semra Palic; Isabelle Köhler; Elizabeth Cunera Maria de Lange
Journal:  Pharm Res       Date:  2018-02-15       Impact factor: 4.200

7.  Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation.

Authors:  S Natesan; S Ashworth; J Nielsen; S-P Tang; C Salinas; S Kealey; J B Lauridsen; T B Stensbøl; R N Gunn; E A Rabiner; S Kapur
Journal:  Transl Psychiatry       Date:  2014-04-01       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.